This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Classification codes | C84 (KCD-8 / ICD-10) |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| Synonyms | Mycosis fungoides, Sézary syndrome, peripheral T-cell lymphoma (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), subcutaneous panniculitis-like T-cell lymphoma, NK/T-cell lymphoma, nasal type |
| Adult onset | Very high (median age about 55 for mycosis fungoides; about 60 for PTCL; about 44-50 for NK/T lymphoma) |
Contents
| A. | Classification codes | B. | Synonyms |
| 1. | History | 2. | Causes |
| 3. | Genetics | 4. | General epidemiology |
| 5. | Pathophysiology | 6. | Symptoms |
| 7. | Signs | 8. | Screening |
| 9. | Diagnosis | 10. | Treatment |
| 11. | Prognosis | 12. | Prevention |
| 13. | References | ||
| Code | Name |
|---|---|
| C84 | Mature T/NK-cell lymphomas |
| C84.0 | Mycosis fungoides |
| C84.1 | Sézary syndrome |
| C84.4 | Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) |
| C84.5 | Other mature T/NK-cell lymphomas (angioimmunoblastic T-cell lymphoma AITL, nodal peripheral T-cell lymphoma, etc.) |
| C84.6 | Anaplastic large cell lymphoma (ALCL), ALK-positive |
| C84.7 | Anaplastic large cell lymphoma (ALCL), ALK-negative |
| C84.9 | Mature T/NK-cell lymphoma, unspecified |
Mycosis fungoides (MF), Sézary syndrome (SS), peripheral T-cell lymphoma NOS (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), extranodal NK/T-cell lymphoma nasal type (ENKL), adult T-cell leukemia/lymphoma (ATL), intestinal T-cell lymphoma, subcutaneous panniculitis-like T-cell lymphoma.
The history of T-cell lymphoma begins in the 1960s-70s, when T cells and B cells could first be distinguished. With advances in monoclonal antibody technology in 1975, antibodies recognizing T-cell surface antigens (CD3, CD4, CD8, etc.) were developed, making it possible to distinguish T-cell lymphoma from B-cell lymphoma.
Mycosis fungoides (MF) was first named in 1806 by the French dermatologist Jean-Louis Alibert, who described neoplastic skin lesions sprouting on the skin like mushrooms. The name "mycosis fungoides" has nothing to do with actual fungi; it is a historical name derived from the apparent resemblance of the skin lesions. In 1938, Albert Sézary described a disease with the triad of persistent erythroderma, lymphadenopathy and characteristic malignant T lymphocytes in the blood (Sézary cells), which was named Sézary syndrome.
The history of extranodal NK/T-cell lymphoma, nasal type (ENKL) is particularly important in Asian medicine. Destructive tumors of the nasal cavity and upper airway, called "lethal midline granuloma" or "polymorphic reticulosis" before the 1980s, were reclassified as ENKL in the 1990s when their association with EBV was demonstrated and their NK/T-cell origin was revealed. An epidemiologic feature is that the incidence of ENKL is markedly higher in Korea and East Asia than in the West.
In anaplastic large cell lymphoma (ALCL), the t(2;5)(p23;q35)/NPM-ALK translocation was discovered in 1994, and overexpression of the ALK (anaplastic lymphoma kinase) protein was demonstrated. ALK-positive ALCL has a much better prognosis than ALK-negative, and ALK inhibitors (crizotinib, lorlatinib, brigatinib) have begun to be applied to the treatment of ALK-positive ALCL as well. The 2011 approval of brentuximab vedotin (BV, an anti-CD30 ADC) for relapsed/refractory ALCL was a landmark turning point in T-cell lymphoma treatment, and BV was subsequently introduced into first-line treatment of ALCL.
EBV (NK/T-cell lymphoma nasal type, EBV-positive PTCL): in extranodal NK/T-cell lymphoma, nasal type (ENKL), EBV is detected within tumor cells in virtually 100%. Latent EBV infection (latency II/III) in NK or cytotoxic T cells constitutively activates NF-κB and JAK-STAT signaling through LMP1 and LMP2A, transforming the cells. The high incidence of ENKL in East Asia (Korea, China, Japan) and Central America is presumed to be associated with the high prevalence of a specific EBV genotype (type A EBV) in these regions.
HTLV-1 (adult T-cell leukemia/lymphoma, ATL): Human T-cell lymphotropic virus type 1 (HTLV-1) is the direct cause of adult T-cell leukemia/lymphoma (ATL). ATL develops in about 3-5% of HTLV-1-infected people after a latency of several decades. HTLV-1 is endemic in Kyushu (Japan), the Caribbean, Central Africa, the Middle East and certain areas of South America, and is transmitted vertically (breastfeeding), through sexual contact and by blood transfusion. In Korea, HTLV-1 infection rates are low, so ATL is relatively rare.
Immunodeficiency and autoimmunity: the risk of T-cell lymphoma is increased with immunosuppression after organ transplantation and with congenital immunodeficiency. Angioimmunoblastic T-cell lymphoma (AITL) is often associated with autoimmune features (immunoglobulin abnormalities, positive autoantibodies).
Environmental exposure: chemicals such as herbicides and organic solvents are reported as risk factors for NHL, including T-cell lymphoma. Gluten intolerance (celiac disease) is associated with the risk of enteropathy-associated T-cell lymphoma. The cause of cutaneous T-cell lymphoma (mycosis fungoides) has not yet been clearly established, but persistent antigenic stimulation and immune dysregulation are presumed to be involved.
ALCL (anaplastic large cell lymphoma):
AITL (angioimmunoblastic T-cell lymphoma):
ENKL (NK/T-cell lymphoma, nasal type): JAK3 and STAT3/5 activating mutations are frequent. DDX3X mutation, TP53 mutation and 6q21-q25 deletion (loss of PRDM1, AIM1) are characteristic changes of ENKL. Constitutive activation of the JAK-STAT, NF-κB and PI3K/AKT pathways through EBV LMP1 is the key oncogenic mechanism. P-glycoprotein (MDR1) overexpression is the molecular basis of anthracycline resistance.
MF/SS (mycosis fungoides/Sézary syndrome): characterized by clonal expansion of skin-infiltrating CD4+ T cells. PLCG1, CARD11 and RHOA mutations, TP53 loss and CDKN2A/B loss are frequent in advanced MF. JAK-STAT pathway activation (JAK1/JAK2/STAT3 mutation or activation) is an important mechanism in advanced MF/SS. Mogamulizumab (anti-CCR4) is an approved targeted therapy for MF/SS.
Mature T/NK-cell lymphomas account for about 10-15% of all NHL, are much rarer than B-cell lymphomas, and generally have a poor prognosis.
Features specific to Korea and East Asia: the proportion of T-cell lymphoma is higher in East Asia (Korea, China, Japan) than in the West. In particular, extranodal NK/T-cell lymphoma, nasal type (ENKL) accounts for about 5-10% of all NHL in East Asia, compared with less than 1% in the West. In Korea, ENKL is one of the most common subtypes of T/NK-cell lymphoma. Important studies on the epidemiology and treatment of ENKL are being published by the Asia Lymphoma Study Group.
Epidemiology by subtype:
Pathophysiology of ENKL: EBV latently infects NK cells or cytotoxic T cells, and the latent membrane proteins LMP1 and LMP2A drive key oncogenic signals. LMP1 binds TRAF1/2/3 to activate NF-κB (canonical), and LMP2A activates the PI3K/AKT pathway through SFK kinases. Constitutive activation of the JAK3-STAT3/5 pathway induces proliferation and apoptosis resistance in tumor cells. EBV-infected cells express cytotoxic granules (perforin, granzyme B) that destroy surrounding normal cells, causing necrotic tissue destruction of the nasal cavity and upper airway. 6q21 deletion (loss of PRDM1/BLIMP1) blocks NK differentiation of the tumor cells.
Pathophysiology of AITL: AITL is a clonal proliferation of neoplastic T cells with a follicular helper T cell (Tfh) phenotype (PD-1+, CXCR5+, BCL6+, ICOS+, CD10+). The RHOA G17V mutation interferes with the functions of normal RHOA (cytoskeletal organization, cell migration) and alters VAV1-RHOA signaling, maintaining Tfh differentiation. TET2 and DNMT3A mutations arise first in hematopoietic progenitor cells to form clonal hematopoiesis, and the subsequent addition of RHOA G17V and IDH2 mutations leads to AITL. The abundant vascular proliferation and reactive B cells (especially EBV-positive B-cell hyperplasia) of AITL create its characteristic histology.
Pathophysiology of MF/SS: it originates from clonal expansion of skin-resident memory T cells (CD4+CLA+). Chronic antigenic stimulation (perhaps long-term allergic or autoantigen responses) is presumed to promote the initial clonal expansion. JAK-STAT pathway activation and TCR signaling hyperactivation due to PLCG1 mutation are the key molecular mechanisms of advanced MF. In SS, circulating Sézary cells home to the skin via CCR4, and mogamulizumab (anti-CCR4) blocks this mechanism.
Symptoms of ENKL (nasal type): it initially starts like chronic rhinitis with nasal obstruction, rhinorrhea and recurrent nosebleeds (epistaxis). With progression, midline destruction such as nasal septal perforation, palatal destruction and proptosis is characteristic. Hyponasal voice, dysphagia, ear fullness and hearing loss occur. Non-nasal ENKL (involving the skin, GI tract, testis, liver and spleen) shows various symptoms according to each involved site. B symptoms (fever, night sweats, weight loss) appear in about 30-50%. Elevated EBV plasma DNA (EBV viral load) reflects disease activity. Hemophagocytic lymphohistiocytosis (HLH) is not uncommonly associated, presenting as high fever, splenomegaly, cytopenias and extremely elevated serum ferritin.
Symptoms of MF/SS: MF shows indolent progression over decades. It initially progresses from eczema-like patch lesions to plaque lesions and then to the tumor stage. SS is characterized by the triad of erythroderma (generalized skin redness), severe pruritus, and circulating Sézary cells (≥1,000/μL).
Symptoms of PTCL-NOS, AITL: rapidly progressive generalized lymphadenopathy, splenomegaly and B symptoms. In AITL, autoimmune features (hemolytic anemia, skin rash, arthralgia) are present, and polyclonal hypergammaglobulinemia is characteristic.
ENKL: necrotic ulcerative (ulcer) lesions of the nasal septum or turbinates on nasal endoscopy. Soft tissue swelling. Elevated EBV viral load (quantitative plasma EBV DNA) is an important indicator—used for diagnosis, treatment response and recurrence monitoring. Elevated LDH, and the prognostic index (PINK: Prognostic Index for NK/T-cell lymphoma) score (distant lymph node involvement, age ≥60, non-nasal-type ENKL, elevated EBV-DNA).
AITL: fever, multiple lymphadenopathy, splenomegaly, skin rash (pruritic maculopapular). Autoimmune findings such as hypergammaglobulinemia, Coombs-positive hemolytic anemia, immunoglobulin M-protein and positive rheumatoid factor. Pleural effusion and ascites may be present.
ALCL: generalized lymphadenopathy, skin involvement (cutaneous ALCL is localized and tends to regress spontaneously). B symptoms. Strong CD30 positivity (immunohistochemistry and elevated serum sCD30). ALK protein expression (cytoplasmic or nuclear+cytoplasmic pattern in ALK+ ALCL).
There is no general population screening for T/NK-cell lymphoma. Targeted surveillance is considered in the following high-risk situations. In HTLV-1-endemic areas, HTLV-1 antibody screening is performed in blood donors and pregnant women, and regular blood tests and clinical surveillance in HTLV-1-positive individuals help detect ATL early. In ENKL patients, monitoring of quantitative plasma EBV DNA after treatment can predict relapse weeks ahead of treatment. In patients with suspected hemophagocytic syndrome (high fever, cytopenias, splenomegaly, extremely elevated ferritin), the possibility of T/NK-cell lymphoma, including ENKL, is actively excluded.
Tissue biopsy: sufficient tissue is obtained by excisional or core needle biopsy. In ENKL, repeated biopsies of viable tissue avoiding necrotic areas are often needed when biopsying via nasal endoscopy.
Immunohistochemistry:
Molecular testing: TCR (T-cell receptor) gene rearrangement testing (essential to confirm clonality), EBV-EBER ISH, quantitative EBV plasma DNA (assessment of disease burden and response in ENKL), FISH (NPM-ALK), NGS panel (RHOA, TET2, IDH2, DNMT3A, etc.).
Staging: PET-CT (whole-body staging, essential to identify extranasal involvement in ENKL), CT (chest/abdomen/pelvis), bone marrow biopsy. In AITL, blood tests (polyclonal hypergammaglobulinemia, Coombs, ANA, RF). In MF, skin stage (T stage: proportion of area with patches, plaques, tumors or erythroderma) and blood stage (Sézary cell count) are included in the integrated TNMB staging system.
DDGP regimen (dexamethasone+cisplatin+gemcitabine+pegaspargase) or P-GEMOX (pegaspargase+gemcitabine+oxaliplatin): asparaginase-based regimens have recently become established as standard first-line treatment. Asparaginase exploits the vulnerability of ENKL cells to asparagine deprivation because they do not express asparagine synthetase (ASNS). Radiotherapy: involved-field radiotherapy (50-54 Gy) is central in early-stage (I/II) ENKL. Concurrent or sequential radiotherapy with chemotherapy is standard in stage I/II. SMILE regimen (dexamethasone+methotrexate+ifosfamide+L-asparaginase+etoposide): used in relapsed/refractory or advanced stages, but toxicity (pancreatitis, hepatotoxicity, myelosuppression) can be severe. Autologous hematopoietic stem cell transplantation (ASCT): considered as consolidation in young transplant-eligible patients after achieving complete remission. PD-1/PD-L1 inhibitors: pembrolizumab and sintilimab have shown promising response rates in relapsed/refractory ENKL (ORR 25-50%). EBV-specific CTL (cytotoxic T lymphocyte) therapy is under study.
BV-CHP (brentuximab vedotin+CHP): in 2019, the ECHELON-2 trial demonstrated significant improvement in progression-free survival compared with CHOP (5-year PFS 51.4% vs 43.2%), making it the first-line standard for CD30-positive peripheral T-cell lymphoma (PTCL). CHOP: still used when BV is unavailable or in low-risk ALK+ ALCL. ALK inhibitors (crizotinib, alectinib): under study in patients with relapsed/refractory ALK+ ALCL. Autologous transplantation: ASCT after salvage in relapsed/refractory ALCL.
CHOP or BV-CHP (if CD30-positive) is first-line treatment. ASCT consolidation is standard in transplant-eligible patients after achieving complete remission. For relapsed/refractory disease: romidepsin (an HDAC inhibitor), belinostat, pralatrexate, lenalidomide, and mogamulizumab under study. Enasidenib under study in IDH2-mutant AITL.
Skin-directed therapy (topical steroids, PUVA photochemotherapy, total skin electron beam therapy, topical nitrogen mustard). Systemic therapy: mogamulizumab (anti-CCR4, FDA-approved in 2018 as second-line treatment for CD4+ MF/SS), brentuximab vedotin (CD30-positive MF), vorinostat, romidepsin (HDAC inhibitors). Allogeneic hematopoietic stem cell transplantation offers the only possibility of cure in advanced MF/SS.
| Subtype | 5-year survival | Notes |
|---|---|---|
| ALCL ALK+(BV-CHP) | About 70-80% | Especially good prognosis in young patients |
| ALCL ALK-(BV-CHP) | About 50-60% | |
| AITL | About 30-40% | Median OS about 3 years |
| PTCL-NOS | About 30-40% | |
| ENKL stage I/II (radiotherapy+chemotherapy) | About 50-70% | PINK low-risk group 70-80% |
| ENKL stage III/IV | About 20-30% | Poor prognosis, asparaginase-based treatment |
| MF (early stage) | About 80-90% | Indolent course, survival for decades |
| MF (tumor or erythrodermic stage) | About 30-40% |
In ENKL, the PINK score (Prognostic Index for NK/T-cell lymphoma), EBV DNA level and extranasal involvement are the main prognostic factors. In AITL, the PIT (Prognostic Index for T-cell lymphoma) score and co-occurrence of TP53/TET2/IDH2 mutations are associated with prognosis.
Blocking HTLV-1 transmission: avoiding breastfeeding (HTLV-1-positive mothers), HTLV-1 blood screening and safe sexual behavior are key to preventing HTLV-1 infection and ATL. In Japan, prenatal HTLV-1 screening and avoidance of breastfeeding have reduced new HTLV-1 infections.
EBV surveillance (immunosuppressed patients): early detection of EBV-related lymphoproliferative disorders by monitoring EBV serology and EBV viral load after transplantation. Preemptive rituximab is effective in preventing post-transplant EBV-related lymphoma.
H. pylori eradication: in patients with confirmed H. pylori infection, eradication therapy prevents and treats gastric MALT lymphoma (marginal zone lymphoma), and an association with some PTCL is also under study.
Managing ultraviolet exposure: the cause of mycosis fungoides is unclear, but chronic skin irritation and UV exposure have been suggested as risk factors. Avoiding excessive UV exposure is presumed to contribute partly to preventing cutaneous T-cell lymphoma.